Hapln3 Antibody

What is HAPLN3 and why is it significant for antibody-based research?

HAPLN3 is a 360 amino acid extracellular protein belonging to the HAPLN family. It contains one Ig-like V-type (immunoglobulin-like) domain and two Link domains, which are essential for its function in hyaluronic acid binding and cell adhesion. HAPLN3 is either secreted or functions as an extracellular matrix protein involved in stabilizing the aggregates of proteoglycan monomers with hyaluronic acid in the extracellular cartilage matrix . Due to its wide tissue distribution and role in extracellular matrix organization, HAPLN3 antibodies are valuable tools for investigating extracellular matrix biology, cellular adhesion mechanisms, and related pathological conditions.

Which tissues express HAPLN3 and what is its cellular distribution pattern?

HAPLN3 is widely expressed in most human tissues, with particularly high expression levels observed in the spleen and placenta . The protein is primarily localized in the extracellular matrix, consistent with its function in hyaluronic acid binding. When using HAPLN3 antibodies for immunostaining, researchers typically observe extracellular matrix-associated patterns, though specific distribution can vary depending on the tissue type. The Human Protein Atlas provides validated immunohistochemistry data for HAPLN3 across 44 normal human tissues, which serves as an excellent reference baseline for expected staining patterns .

What types of HAPLN3 antibodies are available for research applications?

Several types of HAPLN3 antibodies are available for research purposes, with varying characteristics:

• Host species variation: HAPLN3 antibodies are commonly developed in rabbit or mouse hosts. For example, Novus Biologicals offers rabbit polyclonal antibodies , while other suppliers provide mouse polyclonal antibodies raised against full-length human HAPLN3 .

• Clonality options: Both polyclonal and monoclonal antibodies are available. Polyclonal antibodies recognize multiple epitopes on the HAPLN3 protein, while monoclonal antibodies target a single epitope with higher specificity .

• Target recognition range: Antibodies may be raised against different regions of the HAPLN3 protein, such as full-length (AA 1-360), specific domains (AA 51-150), or other fragments (AA 18-360) .

• Conjugation varieties: While many HAPLN3 antibodies are unconjugated, conjugated versions with biotin or fluorescent labels (such as AbBy Fluor® 680, 750, or 594) are also available for specialized applications .

What validation methods ensure HAPLN3 antibody reliability?

The reliability of HAPLN3 antibodies is assessed through several validation approaches:

• Standard validation: Based on concordance with available experimental gene/protein characterization data in the UniProtKB/Swiss-Prot database. This validation results in scores of Supported, Approved, or Uncertain .

• Enhanced validation methods:

  • siRNA knockdown: Evaluating the decrease in antibody-based staining intensity upon target protein downregulation

  • GFP-tagged cell lines: Assessing signal overlap between antibody staining and GFP-tagged protein expression

  • Independent antibodies: Comparing staining patterns of two or more independent antibodies directed towards different epitopes on the HAPLN3 protein

• Application-specific validation:

  • For immunocytochemistry: Comparing staining patterns in cell lines with external experimental evidence for protein localization

  • For immunohistochemistry: Assessing staining patterns in normal tissues with scores including Enhanced, Supported, Approved, and Uncertain

• Specificity testing: Some antibodies undergo specificity verification using protein arrays containing the target protein plus hundreds of non-specific proteins to ensure selective binding .

What are the optimal conditions for using HAPLN3 antibodies in immunohistochemistry?

For optimal immunohistochemistry (IHC) results with HAPLN3 antibodies, researchers should consider the following methodological parameters:

How can researchers troubleshoot non-specific binding when using HAPLN3 antibodies?

When encountering non-specific binding with HAPLN3 antibodies, researchers can implement several troubleshooting strategies:

• Antibody titration: Testing a range of antibody dilutions beyond the manufacturer's recommendation can help identify the optimal concentration that maximizes specific signal while minimizing background.

• Blocking optimization: Extend blocking times (30-60 minutes) and test different blocking agents (5% normal serum from the secondary antibody species, 1-3% BSA, or commercial blocking solutions) to reduce non-specific interactions.

• Secondary antibody controls: Include controls that omit the primary HAPLN3 antibody but include all other reagents to assess background from the detection system.

• Absorption controls: Pre-absorb the HAPLN3 antibody with recombinant HAPLN3 protein to confirm binding specificity. Significant reduction in signal after pre-absorption indicates specific antibody binding.

• Alternative fixation methods: If using HAPLN3 antibodies for immunocytochemistry, compare different fixation protocols (paraformaldehyde, methanol, or acetone) as epitope accessibility can vary with fixation method.

• Cross-reactivity assessment: For some applications, particularly when studying HAPLN family proteins, consider potential cross-reactivity with other family members and include appropriate controls.

What approaches are recommended for validating HAPLN3 antibody specificity beyond manufacturer testing?

Researchers should implement independent validation strategies to ensure HAPLN3 antibody specificity:

• Genetic knockdown/knockout validation: Using siRNA to downregulate HAPLN3 expression or CRISPR-Cas9 to generate knockout cell lines provides compelling evidence of antibody specificity when signal reduction correlates with decreased HAPLN3 expression .

• Multiple antibody validation: Utilizing two or more antibodies targeting different HAPLN3 epitopes (e.g., one targeting AA 1-360 and another targeting AA 51-150) and demonstrating consistent staining patterns strongly supports antibody specificity .

• Recombinant expression systems: Overexpressing tagged versions of HAPLN3 (such as GFP-fused HAPLN3) and demonstrating co-localization with antibody staining provides additional validation .

• Mass spectrometry correlation: For Western blot applications, excising the band recognized by the HAPLN3 antibody and confirming its identity through mass spectrometry offers definitive validation.

• Peptide competition assays: Comparing antibody staining patterns with and without pre-incubation with the immunizing peptide can help verify epitope-specific binding.

• Tissue panel comparison: Analyzing antibody staining patterns across multiple tissues and comparing them with known HAPLN3 expression profiles from transcriptomic datasets helps confirm biological relevance of the staining patterns.

How can HAPLN3 antibodies be optimized for dual immunofluorescence studies?

To achieve optimal results in dual immunofluorescence studies with HAPLN3 antibodies:

• Host species compatibility: Select HAPLN3 antibodies from a different host species than the second target protein's antibody to avoid cross-reactivity during secondary antibody detection. For instance, combine rabbit polyclonal HAPLN3 antibodies with mouse antibodies against other proteins of interest .

• Sequential staining protocols: For challenging combinations, implement sequential staining protocols with intermittent blocking steps using excess unconjugated secondary antibodies to prevent cross-reactivity.

• Direct conjugation options: Consider using directly conjugated HAPLN3 antibodies (e.g., those with AbBy Fluor® 680, 750, or 594) to eliminate secondary antibody cross-reactivity concerns .

• Spectral separation: When selecting fluorophores, ensure adequate spectral separation to minimize bleed-through between channels. For colocalization studies with HAPLN3, combining green fluorophores (FITC, Alexa 488) with far-red fluorophores (Cy5, Alexa 647) typically provides optimal separation.

• Fixation compatibility: Optimize fixation protocols to preserve both HAPLN3 epitopes and those of co-stained proteins, as different proteins may require different fixation conditions for optimal antibody accessibility.

What methodological considerations are important when using HAPLN3 antibodies in disease-related research?

When employing HAPLN3 antibodies in disease-related research contexts:

How can HAPLN3 antibodies be employed to investigate extracellular matrix organization?

To investigate HAPLN3's role in extracellular matrix organization:

• Co-localization studies: Combine HAPLN3 antibodies with antibodies against other extracellular matrix components (hyaluronic acid, proteoglycans, collagens) using multi-channel immunofluorescence to visualize spatial relationships.

• Proximity ligation assays: Employ proximity ligation assays using HAPLN3 antibodies paired with antibodies against potential binding partners to visualize and quantify protein interactions within the extracellular matrix with nanometer resolution.

• Functional blocking experiments: Use HAPLN3 antibodies in functional blocking experiments to disrupt HAPLN3-mediated interactions and observe consequent alterations in matrix architecture.

• 3D culture models: Apply HAPLN3 immunostaining to 3D cell culture models that better recapitulate the native extracellular matrix environment compared to standard 2D cultures.

• Super-resolution microscopy: Combine HAPLN3 antibody staining with super-resolution microscopy techniques (STED, STORM, PALM) to visualize nanoscale organization of HAPLN3 within the extracellular matrix network.

What role can HAPLN3 antibodies play in investigating the protein's involvement in moyamoya disease?

Recent research has implicated HAPLN3 variants, particularly p.T34A, in modifying the penetrance of moyamoya disease associated with RNF213 p.R4810K mutations . To investigate this connection using HAPLN3 antibodies:

• Genotype-phenotype correlation studies: Compare HAPLN3 antibody staining patterns in vascular tissues from patients with different HAPLN3 genotypes (wild-type versus p.T34A variant) to identify potential alterations in protein localization or expression levels.

• Angiogenesis model analysis: Use HAPLN3 antibodies in tube formation assays with human brain microvascular endothelial cells transfected with wild-type versus mutant HAPLN3 to visualize differences in angiogenic potential .

• Protein-protein interaction changes: Employ co-immunoprecipitation with HAPLN3 antibodies followed by mass spectrometry to identify potential differences in interaction partners between wild-type and T34A variant HAPLN3 in vascular contexts.

• Protein stability assessment: Use HAPLN3 antibodies in pulse-chase experiments to determine whether the T34A variant affects protein stability or turnover rates, potentially explaining its impact on disease penetrance.

• Histopathological analysis: Apply HAPLN3 antibodies to cerebrovascular specimens from moyamoya disease patients to assess potential alterations in protein distribution in affected vessels compared to controls.